Help Desk

860-305-6955

Invest

Partner with us to advance groundbreaking solutions in pain and addiction treatment while driving long-term value.

Phoenix has received strong validation of its science from the NIH and the DoD, which together awarded the company grants of more than $12 million to fund the advancement of its compounds. Grant funds have been supplemented with approximately $10 million of private equity investment including a $2 million online public offering of private securities that were oversubscribed under SEC Rule CF. The company is currently applying for additional grants as well as raising funds through private equity investment to fund the further advancement of its compounds.

Reasons to Invest

  • Three shots on goal: pain, addiction & PTSD/AUD
  • Large & growing $30B+ unmet medical need: The Opioid crisis
  • Robust IP 
  • Deeply experienced team
  • Acquisition or out-license exit: 2027 / 2028
  • “Bench” of 25 additional drug candidates
  • Significant past and present non-dilutive funding with strong validation of the science and the team by the NIH and the DOD.
  • Government, industry, and the medical field have great ethical and financial motivation to see the opioid problem solved
  • PPL-138 has been studied at multiple universities and research institutions.

Investment Opportunities

Contact us

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.

Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.

The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.